NCT04393038Phase 2, phase 3Terminated

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Study sponsor: Abivax S.A. · ABVX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-03-05Actual
Enrollment · participants509Actual
Source updated2025-11-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive. After: Measure: Rate of Responders: i.e. Rate of Patients Who do Not Require Use of High-flow Oxygen Invasive or Non-invasive Mechanical Ventilation (IMV and NIV, Respectively) Within 28 Days and Who Are Alive at the End of the 28 Days Period..

Check registry source